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Degenerative mitral valve disease often leads to leaflet prolapse due to chordal elongation or rupture, and resulting in mitral valve regur-
gitation. Guideline referral for surgical intervention centres primarily on symptoms and ventricular dysfunction. The recommended treatment
for degenerative mitral valve disease is mitral valve reconstruction, as opposed to valve replacement with a bioprosthetic or mechanical valve,
because valve repair is associated with improved event free survival. Recent studies have documented a significant number of patients are not
referred in a timely fashion according to established guidelines, and when they are subjected to surgery, an alarming number of patients
continue to undergo mitral valve replacement. The debate around appropriate timing of intervention for asymptomatic severe mitral
valve regurgitation has put additional emphasis on targeted surgeon referral and the need to ensure a very high rate of mitral valve
repair, particularly in the non-elderly population. Current clinical practice remains suboptimal for many patients, and this review explores
the need for a ‘best practice revolution’ in the field of degenerative mitral valve regurgitation.
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Introduction
Degenerative mitral valve disease is a common disorder affecting
around 2% of the population.1 The most common finding in
patients with degenerative valve disease is leaflet prolapse due to
elongation or rupture of the chordal apparatus, resulting in
varying degrees of mitral valve regurgitation due to leaflet malcoap-
tation during ventricular contraction. The emphasis of clinical
decision-making in patients with degenerative disease centres
around the severity of regurgitation and its impact on symptom
status, ventricular function and dimension, the sequelae of systolic
flow reversal such as atrial dilatation/fibrillation and secondary
pulmonary hypertension, and the risk of sudden death.1–4
Controversy exists as to whether early surgical intervention in
asymptomatic patients, before the onset of ventricular changes,
improves the outcome of patients with chronic severe degenerative
mitral valve disease.4–7 This debate has put emphasis on the lack of
predictability of mitral valve repair, despite broad consensus that
this is the procedure of choice for patients undergoing surgical inter-
vention. The confidence gap in predicting successfulmitral valve repair
is one of the factors responsible for the lackof adherence to guidelines
directed toward timely referral of patientswith indications for surgery.
An emerging accord is building that current medical and surgical prac-
tice often results in suboptimal care for the individual patient with
degenerativemitral valve disease, and indeed a paradigm shift or ‘revo-
lution’ through education is not only predictable but essential to
advance the field. All practicing cardiovascular specialists should
have familiarity with the ‘state of art’ in terms of degenerative
disease differentiation, timing of intervention, and surgical techniques
and results in order to improve patient care.8
The spectrum of degenerative
mitral valve disease
Mitral valve prolapse due to degenerative disease is defined by a
spectrum of lesions, varying from simple chordal rupture involving
* Corresponding author. Tel: +1 212 659 6820, Fax: +1 212 659 6818, Email: david.adams@mountsinai.org
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2010. For permissions please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org.
European Heart Journal (2010) 31, 1958–1967
doi:10.1093/eurheartj/ehq222
prolapse of an isolated segment (most commonly the middle
scallop of the posterior leaflet) in an otherwise normally shaped
valve, to multi-segment prolapse involving one or both leaflets in
a valve with significant excess tissue and large annular size; thus,
a spectrum of degenerative disease is evident in clinical practice,
which has important clinical and surgical implications (Figure 1).8–11
Fibroelastic deficiency
Fibroelastic deficiency is a condition characterized byCarpentier and
co-workers, who realized that not all degenerative valve disease
involved giant excess tissue as originally proposed by Barlow in the
1960’s.12–13 Carpentier described a condition associated with a
fibrillin deficiency which often leads to a rupture of one or more
thinned and elongated chordae, usually involving the middle
scallop of the posterior leaflet. In selected cases valve segments
may appear completely normal with the isolated finding of thinned
chordae (Figure 1). In other patients, the prolapsing segment devel-
ops myxomatous changes with mucopolysaccharide accumulation
in the valve mucosa, causing a proliferative condition of the affected
leaflet segment (Figure 1). The key tomaking the distinction of fibroe-
lastic deficiency rests in the condition of adjacent leaflet segments,
which are usually normal or even thinned out with a translucent
quality, and are of normal size and height (Figure 2A).9–11 The valve
annular size as defined by anterior leaflet surface area (measured
with commercially available ring sizers) is generally normal (28–
32 mm).11 Patients are typically over the age of 60 years at the
time of surgical referral, and have a relatively short clinical history.
Echocardiographic findings include an isolated segmental prolapse
due to chordal rupture leading to holosystolic mitral regurgitation,
evident on echocardiographic imaging (Figure 2B and C ).14–15
Barlow’s disease
In contrast to fibroelastic deficiency, Barlow’s disease is character-
ized by diffuse excess tissue (Figure 1).9–11,16–17 Valve size is
generally quite large, and multiple segments are usually affected
with myxomatous pathological changes, resulting in ‘floppy leaflets’
that are thickened and distended. Diffuse chordal elongation in
addition to chordal rupture is the rule as opposed to a simple isolated
chordal rupture. Typically the valve size based on anterior leaflet
surface area corresponds to a mitral ring size of ≥36 mm. Severe
annular dilatation with varying degrees of annular calcification may
be observed, and subvalvular fibrosis and calcification of the papillary
muscles (usually the anterior papillary muscle) may occur.17 Patients
with Barlow’s disease are generally younger (,60 years of age) at the
time of surgical referral, and typically have a long history of a regur-
gitant murmur.9–10 Forme fruste was the descriptive label Carpen-
tier gave to certain mitral valves with some but not all pathologic
features of Barlow’s disease, recognizing there was a spectrum of
lesions.10–11 Echocardiographic findings include mid-systolic and
often complex regurgitation with multiple jets consistent with
diffuse myxomatous disease (Figure 2C and D).14–15 Billowing of
one or both leaflets is often seen. The posterior leaflet is often dis-
placed toward the left atrial (LA) free wall away from the ventricular
hinge, resulting in a cul-de-sac along the posterior portion of the
annulus, which may be a precipitating factor for annular fissures
and calcification.17–18
Echocardiographic assessment
of mitral regurgitation
Echocardiography is the diagnostic method of choice to assess
patients with mitral valve disease. The identification of the aetiol-
ogy and underlying lesions that result in mitral valve dysfunction
is of particular importance for management decisions; patients
with degenerative mitral regurgitation should be differentiated
from those with other forms of mitral disease such as rheumatic
or functional mitral regurgitation. A precise morphologic assess-
ment is necessary to predict the rates of successful reconstructive
valve surgery. In most cases, the aetiology and localization of the
pathology (assessment of the involved leaflets and segments) can
Figure 1 Spectrum of degenerative mitral disease. There is a spectrum of degenerative disease ranging from fibroelastic deficiency (FED) to
Barlow’s disease. In isolated FED there is a deficiency of collagen, with thin transparent leaflets and typically a ruptured thin chord. In long-
standing prolapse, secondary myxomatous pathologic changes may occur in the prolapsing segment, resulting in leaflet thickening and expansion
(FED+). Forme fruste designates degenerative disease with excess tissue with myxomatous changes in usually more than one leaflet segment,
but usually does not involve a large valve size, distinguishing it from Barlow’s disease. In the later, the hallmarks are large valve size, with diffuse
myxomatous changes and excess leaflet tissue, with thickened, elongated, and often ruptured chordae.
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be identified by transthoracic echocardiography.19 A systematic
approach is recommended, since a combination of lesions may
be contributing to the valve dysfunction and a satisfactory correc-
tion requires addressing all of them at the time of surgery. Trans-
oesophageal echocardiography allows a more precise assessment
and should be performed when the information obtained by trans-
thoracic echocardiography is insufficient. Intraoperative transoeso-
phageal echocardiography is nowadays systematically performed in
mitral repair surgery and provides important information, and
allows for an immediate assessment of the operative result. The
availability of 3D echocardiography provides additional information
to determine the exact localization of lesions.15,20
The echocardiographic quantification of mitral regurgitation
severity is sometimes challenging and should comprise an integra-
tive approach of qualitative and quantitative signs.21 Because of its
clinical implication, the identification of severe mitral regurgitation
is of particular importance. Several parameters that can be cate-
gorized into structural, Doppler echocardiographic and quantitat-
ive parameters should be assessed and considered together for
the quantification of mitral regurgitation severity.21 In addition to
quantitative parameters, specific and supportive signs of severity
have been defined. Specific signs for the presence of a severe
mitral regurgitation include a vena contracta width ≥0.7 cm with
a large central regurgitant jet (area .40% of left atrium) or with
a wall-impinging jet of any size, a large flow convergence, systolic
flow reversal in the pulmonary veins and a prominent flail mitral
valve leaflet or ruptured chordal apparatus. Supportive signs
include a dense, triangular CW Doppler MR jet, an E-wave domi-
nant mitral inflow (E . 1.2 m/s) as well as an enlarged left ventri-
cular (LV) and LA (particularly with normal LV function). Among
the quantitative parameters, an effective regurgitant orifice area
≥40 cm2, a regurgitant volume ≥60 mL, and a regurgitant fraction
≥50% characterize severe mitral regurgitation. Since most of the
above measurements have limitations, the information of several
factors should be combined. In addition, echocardiography allows
assessments of pulmonary arterial pressure and LV size and func-
tion, which are all important in the timing of mitral valve surgery.
The assessment of the severity of mitral regurgitation should be
correlated with clinical evaluation.
Timing of surgery
Surgical intervention for chronic severe mitral valve regurgitation is
usually triggered by the occurrence of symptoms, declining LV
function, significant LV enlargement, or the development of atrial
fibrillation or severe pulmonary hypertension.22–23 Over the
past few years the concept of earlier surgical intervention has
been proposed, although controversy exists whether asympto-
matic patients with severe mitral regurgitation and normal LV func-
tion should undergo elective mitral valve repair.4–5,7,24–26
Although the debate regarding asymptomatic patients is ongoing,
emerging data suggest a wide clinical practice gap in appropriate
referral of patients with guideline-defined indications for surgical
intervention; both issues are clarified below.
The debate around patients with
asymptomatic severe mitral
regurgitation
Enriquez-Sarano et al.4 noted high event rates, including sudden
death, in 198 asymptomatic patients with quantitatively graded
Figure 2 Echocardiographic differentiation of degenerative mitral disease. (A) Fibroelastic deficiency with a ruptured thin chord to P3 (posterior
lateral scallop). (B) Three-dimensional transoesophageal echocardiography volume rendering of the same valve. (C) Three-dimensional rendering
of the same valve from a three-dimensional data set using quantitative analysis (red area corresponds to prolapsing area). (D) Barlow’s disease with
multi-segment prolapse and excess leaflet tissue. (E) Three-dimensional rendering volume rendering of the same valve. (F) Three-dimensional
rendering of the same valve from a three-dimensional data set using quantitative analysis (red areas correspond to prolapsing areas).
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severe degenerative mitral regurgitation (effective regurgitant
orifice area ≥40 mm2), leading them to recommend prompt
surgery in such patients. However, in this study patients were
not prospectively followed and included some patients with an
ejection fraction between 50 and 60%, which would be operated
according to recent guidelines. In contrast, Rosenhek et al. pub-
lished a contemporaneous series involving 132 asymptomatic
patients with semi-quantitatively graded severe degenerative
mitral regurgitation and noted a good outcome with a watchful
waiting strategy. During an 8-year interval, 45% of patients had
an event (but not sudden death), with events occurring at a
regular pace. Two-thirds of the patients fulfilling indications for
surgery became symptomatic, whereas one-third of the patients
required surgery because of asymptomatic LV dysfunction or
enlargement, or new onset atrial fibrillation or pulmonary hyper-
tension.7 Kang et al.5 published the results of their prospective reg-
istry involving 161 asymptomatic patients with semi-quantitatively
graded severe degenerative mitral regurgitation who were sub-
jected to early surgery, compared with 268 similar patients
managed by watchful waiting over a 9 year period of follow-up.
They found a 99% cardiac event-free survival in operated patients,
compared with 85% in patients under a strategy of continued
medical observation. The cardiac deaths occurring in the group
of patients that was initially managed conservatively, however,
may have not have been related to conservative strategy; urgent
surgery was proposed but refused by five of the six patients
who died of congestive heart failure and one sudden death
occurred in a patient who had become symptomatic. Nonetheless
three cases of sudden death occurred in asymptomatic patients.
Montant et al.6 recently examined outcomes in patients with
severe degenerative mitral regurgitation by semi-quantitative echo-
cardiographic assessment, reporting on 67 patients managed with a
conservative approach and 125 patients subjected to early mitral
valve repair. Ten year survival was significantly lower in conserva-
tively managed patients compared with those operated early
(50+7% vs. 86+4%, P, 0.0001). Interestingly, these authors
also documented better survival and higher referral to surgery in
conservatively managed patients seeing cardiologists regularly
compared with those with irregular follow-up, but their survival
still did not match those subjected to early surgery.
Unfortunately, no attempt was made in any of these studies to
differentiate the aetiology of degenerative mitral valve disease,
although patients were older in Enriquez-Sarano’s study (mean age
63+14 years) and Montant’s study (mean age 63+13 years) vs.
Rosenhek’s study (mean age 55+15 years) and Kang’s study
(mean age 50+15 years), suggesting that more patients in the
Mayo and Brussels series may have had fibroelastic deficiency. The
results of Rosenhek et al. emphasized the need for careful patient
and echocardiographic assessment in a dedicated valve clinic with
strict adherence to guideline referral if a strategy of watchful
waiting is undertaken, a point reinforced by Montant’s data.
Several additional prognostic factors allowing to risk stratify
asymptomatic patients with mitral valve regurgitation have been
proposed. Pizarro et al.27 have shown that low brain natriuretic
peptide levels (,105 pg/mL) are associated with a stable disease
course whereas higher levels may predict an unfavourable
outcome. A good exercise tolerance has been shown to be
associated with a higher event-rate.28 Left atrial size may also be
related to outcome. Recently, Tribouilloy et al.29 have shown
that a LV end-systolic diameter ≥40 mm is independently associ-
ated with increased mortality under medical management and
after surgery. Current European guidelines recommend mitral
valve surgery when the LV end-systolic diameter is larger than
45 mm as compared with 40 mm for North American Guidelines
and these data favour the latter approach.22–23 Recent data from
the Mayo group also suggest superior recovery of long-term LV
ejection fraction following early mitral valve repair when the pre-
operative ejection fraction is ≥65% (current guidelines rec-
ommend surgery when the ejection fraction is ≤60%).30
Referral of patients with
symptoms and/or left ventricular
dysfunction
Symptoms and LV dysfunction are guideline triggers for surgical
referral of patients with severe mitral valve regurgitation.22–23
Interestingly, recent studies have documented a widespread discor-
dance in ‘real world’ surgical referral of patients who have an
obvious Class I indication for surgery. In 2007, Mirabel et al.
found that 49% of patients with symptomatic mitral regurgitation
of various etiologies from the Euro Heart Survey were denied sur-
gical referral. Although frequently unjustified, advanced age,
co-morbidities, and an abnormal ejection fraction were the argu-
ments used to deny surgery.31 Detaint and colleagues later ident-
ified 101 patients within the Euro Heart Survey with isolated
severe non-ischaemic mitral regurgitation and found intervention
was ‘underused’ in 29 patients (29%) although they had no ident-
ified co-morbidities and fulfilled guideline recommendation criteria
for surgery.23 Toledano et al.32 surveyed approximately 300 cardi-
ologists in Canada, half of whom were in a university practice
whereas the other half were in a community setting to gauge
their knowledge of North American referral guidelines of patients
with severe mitral valve regurgitation. Nearly 40% of those cardi-
ologists indicated that they would wait for the ejection fraction
to fall below 40% or wait for symptoms to occur before referring
an asymptomatic patient for surgery with severe mitral valve regur-
gitation, despite a Class I guideline recommendation for referral if
the ejection fraction is equal to or falls below 60%. Recently, Bach
et al.33 assessed the frequency at which adult patients at the Uni-
versity of Michigan with severe mitral valve regurgitation documen-
ted on an echocardiogram were denied surgery. Fifty-three of 112
patients with severe degenerative mitral regurgitation were not
referred for surgery, although 39 of 53 patients (74%) had one
or more indications for surgical intervention according to
current North American guidelines.22 Interestingly, no patients
that were referred to a surgeon for evaluation were thought to
have a risk too high for surgical intervention during the study
period, yet several patients ‘denied surgical referral’ subsequently
died. The authors concluded that much of the ‘perceived risks’
leading to a denial of referral were incorrectly interpreted by car-
diologists or other referring physicians. All of these data point
towards the need for continued medical education of practicing
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clinicians to increase familiarity with current guidelines, which will
lead to more appropriate referral of patients to surgery.
Who should operate
It is well accepted that the majority of patients with degenerative
mitral valve disease who require surgery will have an improved
quality of life with less morbidity as well as better long-term survi-
val if a valve repair as opposed to replacement is performed.34–37
This is related primarily to prosthesis-related morbidity, including
higher re-operation rates, and the need for aggressive anticoagula-
tion. It is sobering to note that even in developed countries, mitral
valve replacement remains frequent in the setting of degenerative
disease. Gammie et al.38 reported that the repair rate for patients
(n ¼ 47 126) with isolated mitral regurgitation in the Society of
Thoracic Surgeons (STS) Adult Cardiac Surgery Database rose
from 51 to 69% between January 2000 and December 2007.
Similar repair rates in the 50% range were documented in the
Euro Heart Survey. The reality is that mitral valve replacement
continues to be performed far too frequently in the modern era
of reconstructive valve surgery.39
Many recent reports document repair rates in excess of 90% in
centres highly skilled in mitral valve repair,40–42 suggesting an
ongoing ‘gap’ in best practice surgical care of patients with degenera-
tive disease of at least 20%, which translates into a significant inci-
dence of unnecessary mitral valve replacement. This quality
measure reinforces a recommendation in the current North Amer-
ican guidelines: ‘. . . cardiologists are strongly encouraged to refer
patients who are candidates for mitral valve repair, to surgical
centers experienced in performing mitral valve repair’.22 Others
have suggested that patients with Barlow’s valve disease (which typi-
cally present with more complex lesions) be specifically targeted for
referral to mitral valve ‘reference surgeons’.43–45 Since patients with
Barlow’s disease are typically younger and therefore likely to have
the greatest benefit from valve repair instead of replacement, this
strategy seems to be particularly relevant. The localization of
leaflet prolapse (posterior, anterior, or bileaflet) is also of prognos-
tic relevance since many reported series suggest much lower repair
rates for anterior or bileaflet prolapse compared with posterior
leaflet prolapse.45–47 Taking these factors into consideration
allows a recommendation for targeted surgeon referral of certain
patients with degenerative disease (Table 1).
Recent studies have documented that operative mortality
rates and perioperative morbidity are lower in high volume
mitral surgical centres, providing additional emphasis on a best
standard practice of trying to concentrate surgical volume of
degenerative mitral valve disease in selected centres.48 Although
high volume is also generally associated with higher rates of
mitral valve repair, this is not always the case. In a report published
early this year from the Society for Cardiothoracic Surgery in
Great Britain and Ireland involving over 5000 mitral operations
for degenerative disease performed in either country over a
6-year-period, one of the 10 highest volume centres had a mitral
valve repair rate of ,40%.49 Furthermore, even in high volume
mitral repair centres, it is important to differentiate surgical exper-
tise among individual surgeons. In a single-institution series of more
than 3200 mitral surgeries, although the institutional repair rate
was 93%, in a multivariate analysis of the individual surgeon’s
performances, only one surgeon in this institution was predictive
of a higher rate of repair.36
Ongoing assessment of actual vs. predicted repair rates as
well as quality of repair judged by residual mitral regurgitation
rates are also important quality measures. Today no more than
5–10% of patients should undergo an ‘un-anticipated replacement’
or have more than mild residual regurgitation if operated on in a
‘reference centre’.40 Particularly in the asymptomatic patient, the
role of such assessments of quality by means other than mortality
rates (which are around 1% in contemporary practice) will take on
increasing importance.
Current operative strategies
and results
Mitral valve repair operative strategies and techniques continue to
evolve, with significant changes seen over the past decade.
Surgical access
Traditionally, mitral valve repair procedures have been performed
through a 15–20 cm skin incision and full median sternotomy.
Other less invasive approaches, including limited sternotomy or
small skin incision (8–10 cm)-full sternotomy, and right sided mini-
thoracotomies with or without video assistance (Figure 3) are now
successfully performed in many expert centres.41–42,50–52 These
approaches are associated with higher patient cosmetic satisfac-
tion; lesser blood transfusion has been reported in some series,
at the expense of longer cross-clamp times.
The right thoracotomy approach is often used in the redo
setting, as it avoids the need for repeat sternotomy and requires
less dissection of the heart. Completely endoscopic robotic valve
repair has been reported to be feasible and reproducible in
expert centres53 and has been embraced in selected high volume
Table 1 Targeted surgeon referral: degenerative
mitral valve disease
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centres, particularly in the USA. Higher costs, undocumented
benefit, and the extensive learning curve associated with robotic
approaches likely explain slow adoption.54
Repair techniques
The goal of a mitral valve repair procedure for degenerative
disease follows two fundamental principles: restore a good
surface of leaflet coaptation and correct for annular dilata-
tion.55–56 A leaflet coaptation line of 5–8 mm is considered essen-
tial to provide a durable repair result. To select the most
appropriate repair technique a complete understanding of the
underlying degenerative aetiology, anatomical lesions, and leaflet
dysfunction (excess or restricted leaflet motion) is mandatory.
Intraoperative transoesophageal 2D and increasingly real time 3D
transoesophageal echocardiography is applied to guide the pro-
cedure and confirm a good result.14–15
In terms of valve repair procedures, two paradigms have
emerged with strong proponents. Carpentier’s techniques which
generally involve resection of abnormal or pathologic tissue with
precise reconstruction toward essentially ‘normal valve anatomy’
(Figure 4) remain the most commonly performed world-wide,
and are associated with excellent long-term outcomes.10,55–58 In
the most common scenario, isolated prolapse of the posterior
leaflet is treated by a limited triangular or quadrangular leaflet
resection, including the respective elongated or ruptured
chordae. The remnant leaflet margins are then readapted using
interrupted sutures. If larger resections of abnormal tissue are
required such as seen in Barlow’s disease, then the annulus is com-
pressed with additional interrupted sutures to narrow its circum-
ference resulting in less tension on residual reconstructed leaflet
segments.10 All resections of tissue are targeted to restore the
normal height and shape of residual leaflet segments, and to
restore the normal relationship of anterior and posterior leaflet
surface area to the normal annular dimension for a given
patient. This is critical to avoid systolic anterior motion of the
anterior leaflet after valve repair.59–60 If residual prolapse
remains despite tailored resections of abnormal tissue, then trans-
fer of secondary chords to the free margin of the same segment,
or chordal transposition from one segment to another is per-
formed. For example, in the later scenario a ‘flip’ of a small
segment of normal posterior leaflet with chords to an opposing
segment of a prolapsing anterior leaflet segment can restore
normal leaflet motion.61
An emerging paradigm of ‘respect rather than resect’ tissue has
become popular in recent years, and is based on the use of poly-
tetrafluoroethylene (PTFE) neochordae to reconstruct support of
the free edge of prolapsing segments, and ‘displacing’ abnormal
excess tissue into the ventricle to ensure a good surface of coapta-
tion without systolic motion of the anterior leaflet.62–63 Variations
of this technique have been described, and a ‘loop technique’
where the PTFE is anchored into a papillary muscle tip and then
branches or ‘loops’ are attached to the free edge mimicking a
chordal fan is perhaps the most widely used (Figure 4). Depending
on the individual anatomy the neochordae are anchored on the
anterior or posterior or papillary muscle heads in their fibrous
portion, respecting a policy of not crossing the midline or individ-
ual native chordae in order to prevent excess traction on the
leaflet margin. In the case of significant excess posterior leaflet
height, the neochordae are made short enough to displace the
prolapsing segment into the left ventricle, to ensure a large
surface of coaptation for the anterior leaflet while preventing
anterior leaflet displacement in the outflow tract. Early results
with have been encouraging and no or limited leaflet resection in
combination with PTFE loops is now a preferred technique in
many centres today. The simplicity of the technique is particularly
relevant in small access incisions where more advanced Carpentier
techniques may prove challenging (Figure 5).
Calcification of the chordae, papillary muscles, leaflets, and
annulus may occur in the setting of degenerative valve disease.17
In general, debridement of calcified tissue is required to restore
a good mobility to leaflet tissue, and to ensure an adequate
surface of coaptation. Mitral annular calcification can pose a
special challenge to valve reconstruction, particularly when it is
diffuse. In certain circumstances it is possible to ‘respect’ the
calcium, placing pledgeted sutures on the ventricular side of the
calcium and passing them through the ring on the atrial side. Some-
times it is necessary to perform an ‘en bloc’ resection of the
calcium bar in the annulus, separating the atrioventricular groove.17
Regardless of the leaflet and chordal techniques employed, a
prosthetic ring or band annuloplasty that restores the normal cir-
cumference and shape of the mitral valve to match the available
leaflet tissue is a mainstay of all repair procedures.57,64–65 The
fibrous skeleton of the heart is not contiguous around the pos-
terior aspect of the mitral annulus, so long-standing regurgitation
associated with ventricular and atrial enlargement leads to patho-
logic dilatation of the mitral annulus, particularly along the pos-
terior aspect of the valve. Regardless of the type of annular
prosthesis (complete ring, partial posterior band; rigid, semi-rigid,
or flexible), most surgeons measure the surface of the anterior
Figure 3 Mitral surgery via right thoracotomy. The patient is in
a supine position, and cannulated for cardiopulmonary bypass via
the groin vessels. The valve is exposed through a right mini-
thoracotomy and visualization is assisted by a videoscope.
Shown in the inset is the aorta clamped, with a caridioplegia
needle inserted in the aorta, and the mitral valve as seen by
the surgeon with the atrium opened.
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leaflet with a sizer to estimate the appropriate ring size for the
amount of leaflet tissue, although a ‘standard length’ band has
been employed by some groups with excellent results.66 Failure
to perform an annuloplasty at the time of mitral valve repair is
one of the strongest predictors of failure resulting in recurrent
moderate or severe mitral valve regurgitation.67 This may have
important implications for percutaneous techniques that primarily
attempt to address prolapse by attaching opposing leaflets without
concomitantly changing the shape of the annulus.
Mitral valve replacement
In contemporary practice at the reference level, mitral valve repla-
cement for degenerative disease in a primary operation should be a
rare. Many current reports document repair rates in excess of
90%, regardless of lesions or associated leaflet dysfunction.40–42
The most common scenario for a replacement in a high-volume
reference centre should be an end-stage Barlow deformity, typi-
cally seen in older patients with long-standing disease. This scen-
ario is actually uncommon, and if identified preoperatively should
lead to a careful discussion regarding the possibility of replacement,
and assurance that the patient has a Class I indication for surgery. If
valve replacement is necessary, annular-papillary continuity should
be preserved by performing a chordal sparring procedure.68
Although calcified leaflet segments require resection, non-calcified
segments with intact chords are incorporated into the annulus
with sutures that are used to implant the prosthesis.
Mitral valve regurgitation
following mitral valve repair
All patients undergoing mitral valve repair should have a post-
repair intraoperative transoesophageal echocardiogram to
determine the immediate success of the procedure.69 A finding
of more than mild mitral regurgitation should lead the
surgeon, except in certain high-risk patients, to consider valve
re-exploration to identify the source of residual regurgitation.
The most common reasons for a residual post-repair leak are
uncorrected prolapse, separation of a leaflet cleft or indentation,
a defect in a leaflet to leaflet closure line, or a perforation of a
leaflet from a ring suture near the leaflet hinge. In each of these
circumstances, an additional repair technique can address the
cause of valve regurgitation leading to a successful result. The
other scenario that should be ruled out in residual mitral
Figure 4 Triangular resection and ring annuloplasty. (A) Fibroelastic deficiency with P2 (posterior middle scallop) prolapse. (B) Dashed lines
represent area of leaflet to be excised. (C) Reconstructed leaflet after triangular resection. (D) Completed repair after ring annuloplasty.
Figure 5 Gore-Tex loop technique and ring annuloplasty. (A) Fibroelastic deficiency with A3 (anterior lateral scallop prolapse). (B) Gore-Tex
loops are constructed, and the apparatus is attached to the fibrous tip of the papillary muscle. (C) Individual loops are attached to the prolapsing
segment margin. (D) Completed repair after ring annuloplasty.
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regurgitation following mitral valve regurgitation is displacement of
the anterior leaflet towards the outflow tract. Systolic anterior
motion is caused by an excess of leaflet tissue in relation to the
orifice area of the mitral valve, and is caused by inappropriate
ring sizing, or an excess of residual leaflet height, usually involving
the posterior leaflet.59,60 Occasionally systolic anterior motion
resolves with volume loading and increasing afterload, but if it is
persistent, evidenced by residual mitral regurgitation and a signifi-
cant outflow tract gradient, the valve should be reoperated on.
The main surgical strategies to address systolic anterior motion
are leaflet shortening, or posterior leaflet ‘displacement’ of
excess leaflet height into the ventricle and out of the orifice
using a short PTFE chordae. A larger mitral ring annuloplasty
device should also be inserted if there is a question about inap-
propriate sizing during the initial repair procedure.
All patients undergoing mitral valve repair should also have a
pre-discharge transthoracic echocardiogram to assess the repair
result under normal loading and pressure conditions.69 Moderate
or greater regurgitation should lead the surgeon in most circum-
stances to consider valve re-exploration after careful risk assess-
ment of the individual patient. It is always better to address
residual significant mitral regurgitation at this point, instead of
months or years down the road when the re-operation is more
complicated due to adhesions.
An annual echocardiogram is usually performed in patients
who have undergone successful mitral valve repair. A new
mitral regurgitation not seen on early transthoracic follow-up
should be categorized as recurrent mitral regurgitation. The
most common cause of recurrent mitral regurgitation is pro-
gression of the degenerative process which led to the original
valve dysfunction. Leaflet shortening or scarring is another poten-
tial source of recurrent regurgitation, as is a ring dehiscence.
Mitral valve endocarditis, although rare, is also in the differential
of recurrent regurgitation following a successful mitral valve
repair. Pannus in-growth triggered by the mitral annuloplasty
ring is another rare but described cause of failure following a
mitral valve repair.70 Haemolysis in the setting of post-operative
mitral regurgitation is another possible outcome that could lead
to the need for mitral valve re-operation.
Although mitral valve re-repair in the setting of chronic recur-
rent mitral regurgitation has been reported, it is highly dependent
on the surgical expertise of the group performing the procedure.71
In many circumstances a re-repair of the mitral valve is feasible
depending on the anatomy and well identified mechanisms of the
recurrent mitral regurgitation.
Surgical results
Although freedom from re-operation is very low in degenerative
mitral valve surgery (15 year freedom from re-operation is
around 95%),55 recent studies have documented the potential
for recurrence of significant mitral valve regurgitation. Studies by
Flameng et al. and David et al. suggest that a return of moderate
to severe mitral regurgitation occurs in 1–2% of patients per
year during mid-term follow-up.55,67,72–74 This observation
places renewed emphasis on expert mitral surgical repair initially
(not only mitigating mitral regurgitation procedurally, but ensuring
a long surface of leaflet coaptation to minimize the risks of a late
failure), and also on the need to continue to evolve surgical
strategies that will optimize long-term mitral valve repair results.
Long-term survival following mitral valve repair is similar to age
matched controls provided the operation is done in a timely
fashion before the onset of symptoms, ventricular dysfunction or
atrial fibrillation.34–35,75–76 Patients undergoing mitral valve
surgery with advanced symptoms do poorly compared with less
symptomatic patients, so surgery should always be recommended
at the onset of symptoms in otherwise low-risk patients. An ejec-
tion fraction of ≤60% is a trigger for referral to surgery, as long-
term survival is compromised in patients after mitral surgery if
the initial ejection fraction is compromised beyond this point.
Atrial fibrillation is a more controversial indication for surgical
referral, but if present at the time of surgery, patients should prob-
ably also undergo a concomitant modified Maze procedure utilizing
cryothermy or radiofrequency, although evidence-based data are
lacking.77–78 Persistent atrial fibrillation after mitral valve repair is
associated with long-term morbidity including stroke as well as
mortality, and these patients require careful anticoagulation
monitoring.79–80
Best practice revolution
Prevailing data suggest many patients with degenerative mitral valve
disease do not receive state-of-the-art care. Accumulating evi-
dence documents a reluctance of many cardiologists and physicians
following patients with mitral valve regurgitation to refer them for
surgery in a timely fashion, when the maximal benefit from a suc-
cessful mitral valve repair would be realized. The reasons behind
this are certainly multi-factorial, and probably include unawareness
of basic concepts in and recent changes to guidelines and a lack of
confidence in or poor understanding of modern surgical therapy
and results. Both suggest the need for broad continued education
with regard to the indications for intervention for mitral valve
regurgitation. The implementation of dedicated valve clinics
should be encouraged when feasible; a significant outcome
benefit can be achieved when experience is widened with
larger patient volumes. A close cooperation between internists,
imagers, cardiologists, and cardiac surgeons should be promoted,
centred on guideline-driven practice.
Despite surgical progress seen in increasing repair rates, lower
mortality rates, and less invasive approaches, far too many
patients continue to be subjected to unnecessary valve replace-
ment procedures. In this modern era of imaging and degenerative
disease differentiation, it should be very uncommon for a patient
with mitral valve prolapse to have an unexpected valve replace-
ment based on operative findings; if the surgeon or imager
thinks the chances are ,90% for a successful repair, they
should refer the patient (particularly any asymptomatic patient
or a young patient with Barlow’s valve disease) to a reference
surgeon in a regional reference mitral valve centre; hopefully
future evidence of better patient outcomes will support these
recommendations and lead to their incorporation into daily prac-
tice. There are numerous ‘medical geo-political and financial bar-
riers’ to such a transparency in surgical referral, but the patient
with degenerative mitral valve disease deserves the best possible
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chance for a repair procedure, which is associated with lower
long-term morbidity and mortality compared with valve replace-
ment in a majority of patients.
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